소아 환자에서 Stenotrophomonas maltophilia와 인공 환기요법 관련 폐렴에 관한 연구
Stenotrophomonas maltophilia and Ventilator-Associated Pneumonia in Critically Ill Pediatric Patients: a Retrospective Analysis at a Single Center
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
목적: 인공 환기요법 관련 폐렴은 중증 소아 환자에게 있어서 심각한 위협이 될 수 있다. 소아 환자에서Stenotrophomonas maltophilia 에 의한 인공 환기요법 관련 폐렴에 대한 연구는 부족한 실정이다. 본연구는 소아 중환자에서 S. maltophilia 에 의한 인공 환기요법 관련 폐렴의 임상적 특성을 알아보고자하였다. 방법: 2008년 1월 1일부터 2012년 12월 31일까지 삼성서울병원 소아중환자실에 입원한S . maltophilia 로 인한 인공 환기요법 관련 폐렴에 걸린 18세 이하 소아들의 의무 기록을 기초로 한 후향적 연구를 시행하였다. 결과: S. maltophilia 로 인한 인공 환기요법 관련 폐렴으로 진단 받은 총 31명의 환자가 연구 대상에포함되었다. 연령 중앙값은 8개월(범위, 0.5개월-16.6세)이고, 남자는 13명(40.6%)이었다. 환자들의만성질환 분포는 심혈관질환(n=11, 34.4%), 혈액종양질환(n=7, 25.0%), 신경질환(n=4, 12.5%), 호흡기질환(n=3, 9.4%) 그리고 기타(n=4, 12.5%)이었다. 인공 환기요법 관련 폐렴을 진단하기 전 인공 환기요법을 하였던 기간의 중앙값은 14일(범위, 4-256일)이었다. S. maltophilia 인공 환기요법 관련 폐렴후 30일 이내 사망률은 12.5% (4/32) 이었다. 결론: S. maltophilia 는 중증 소아 환자에서 인공 환기요법 관련 폐렴의 원인균으로 반드시 고려되어야할 대상이다. 경험적 광범위 베타-락탐 항생제를 사용하고 있음에도 불구하고 환자 상태가 나빠지고 있다면, 항생제 선택에서 S. maltophila 의 감염을 고려해야 할 것으로 사료된다.
Abstract
Purpose: Ventilator-associated pneumonia (VAP) is a serious threat in critically ill pediatric patients. Data regarding Stenotrophomonas maltophilia VAP in pediatric population is limited. We evaluated the clinical data of S. maltophilia associated VAP in critically ill pediatric patients. Methods: A retrospective chart review was performed in pediatric patients 18 years old or younger who developed S. maltophilia associated VAP at Samsung Medical Center, Seoul Korea from January 2008 to December 2012. Results: A total of 31 patients were identified S. maltophilia associated VAP. Median age was 8 months (range, 0.5 month to 16.6 years) and 13 patients were male (40.6%). Underlying illnesses were cardiologic diseases (n=11, 34.4%), hematologic oncologic malignancies (n=7, 25%), neurologic diseases (n=4, 12.5%), pulmonary diseases (n=3, 9.4%), and others (n=4, 12.5%). The median duration of ventilator use before S. maltophilia VAP diagnosis was 14 days (range, 4-256 days). Overall mortality at 30 days was 12.5% (4/32). Conclusions: S. maltophilia should be also considered as a possible pathogen for VAP in critically ill pediatric patients. Empiric antibiotic choice should include agents that are active against S. maltophilia in patients who are deteriorating on broad spectrum beta-lactam antimicrobial agents.
참고문헌 (20)
- Grgurich PE, "Diagnosis of ventilator-associated pneumonia: controversies and working toward a gold standard", Curr Opin Infect Dis, 26, pp.140~150 (2013)
- Stephen WP, "Health care-associated infections among critically ill children in the US, 2007-2012", Pediatrics, 134, pp.705~712 (2014)
- Dudeck MA, "National healthcare safety network report, data summary for 2013, device-associated module", Am J Infect Control, 43, pp.206~221 (2015)
- Foglia E, "Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients", Clin Microbiol Rev, 20, pp.409~425 (2007)
- Venkatachalam V, "The diagnostic dilemma of ventilator-associated pneumonia in critically ill children", Pediatr Crit Care Med, 12, pp.286~296 (2011)
- Mariki P, "Application of a modified microbiologic criterion for identifying pediatric ventilator-associated pneumonia", Am J Infect Control, 42, pp.1079~1083 (2014)
- Willson DF, "The lack of specificity of tracheal aspirates in the diagnosis of pulmonary infection in intubated children", Pediatr Crit Care Med, 15, pp.299~305 (2014)
- Lakatos B, "Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia", Infection, 42, pp.553~558 (2014)
- Ning BT, "Pathogenic analysis of sputum from ventilator-associated pneumonia in a pediatric intensive care unit", Exp Ther Med, 5, pp.367~371 (2013)
- Ko HK, "Intensive care unit-acquired bacteremia in mechanically ventilated patients: clinical features and outcomes", PLoS One, 8, pp.e83298~ (2013)
- Brooke JS., "Stenotrophomonas maltophilia : an emerging global opportunistic pathogen", Clin Microbiol Rev, 25, pp.2~41 (2012)
- Araoka H, "Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy", Transpl Infect Dis, 14, pp.355~363 (2012)
- Lee MR, "Clinical characteristics and outcomes of patients with pleural infections due to Stenotrophomonas maltophilia at a medical center in Taiwan, 2004-2012", Eur J Clin Microbiol Infect Dis, 33, pp.1143~1148 (2014)
- Bouza E, "Pre-emptive broad-spectrum treatment for ventilator-associated pneumonia in high-risk patients", 39, pp.1547~1555 (2013)
- "Surveillance for ventilator-associated pneumonia (VAP)"[URL]
- "Surveillance for ventilator-associated pneumonia (VAP)"[URL]
- Casado RJ, "Incidence and risk factors for health careassociated pneumonia in a pediatric intensive care unit", Crit Care Med, 39, pp.1968~1973 (2011)
- Gupta S, "A multicentered prospective analysis of diagnosis, risk factors, and outcomes associated with pediatric ventilator-associated pneumonia", Pediatr Crit Care Med, 16, pp.e65~e73 (2015)
- Melsen WG, "Attributable mortality of ventilatorassociated pneumonia: a meta-analysis of individual patient data from randomised prevention studies", The Lancet Infectious Diseases, 13, pp.665~671 (2013)
- Brooke JS, "New strategies against Stenotrophomonas maltophilia : a serious worldwide intrinsically drug-resistant opportunistic pathogen", Anti Infect Ther, 12, pp.1~4 (2014)